A5039012283- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- Biosimilars and Bioanalytical Methods
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Radiopharmaceutical Chemistry and Applications
- Neutropenia and Cancer Infections
- Prostate Cancer Treatment and Research
- Peptidase Inhibition and Analysis
- Blood disorders and treatments
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Colorectal Cancer Treatments and Studies
- Phytoestrogen effects and research
- Colorectal and Anal Carcinomas
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Spacecraft Dynamics and Control
- Histone Deacetylase Inhibitors Research
The Seventh Affiliated Hospital of Sun Yat-sen University
2025
Sun Yat-sen University
2025
Harbin Medical University
2010-2024
Third Affiliated Hospital of Harbin Medical University
2010-2024
Shanghai Innovative Research Center of Traditional Chinese Medicine
2024
Shanghai Jiao Tong University
2024
Hubei Academy of Environmental Sciences
2023
Shihezi University
2023
Shandong First Medical University
2023
Shandong Tumor Hospital
2023
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
<b>Background:</b> The intake of soy isoflavones among women with breast cancer has become a public health concern, because these compounds have weak estrogenic effects. There is little clinical evidence about their safety for patients who are receiving adjuvant endocrine therapy. <b>Methods:</b> For underwent surgery between August 2002 and July 2003 were therapy, we examined associations dietary recurrence death. We measured at baseline using validated food frequency questionnaire....
Introduction: The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) continues to convey inferior survival despite efforts enhance outcomes with novel R-CHOP combinations. Phase II studies have suggested that the addition immunomodulatory agent lenalidomide could ameliorate poor prognostic effect ABC phenotype and improve treatment outcome in this subgroup patients. Methods: global phase III ROBUST trial (NCT02285062) is first compare lenalidomide/R-CHOP (R2-CHOP)...
Treatment options are limited for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) following progression after first-line platinum-based therapy, particularly in Asian countries.
Objective: To investigate whether the histone deacetylase (HDAC) activator ITSA‐1 can ameliorate systemic inflammation after cardiac arrest (CA), thereby enhancing function and neurological outcomes in rats. Materials Methods: Sixty‐nine healthy adult male Wistar rats were subjected to 12 min of CA induced by Vecuronium bromide. The randomly assigned five groups: normal control, sham operation, suberoylanilide hydroxamic acid (SAHA), ITSA‐1. study evaluated effects on function, survival,...
Background and Aims. The distal transradial access (dTRA) is a new puncture site for coronary catheterization. We sought to evaluate the feasibility, safety, complication rates of using dTRA cardiac catheterization in Chinese patients. Methods. A total 263 consecutive patients who underwent through were enrolled. primary endpoint study was rate conversion another due impossibility successful artery or intubation. Secondary safety endpoints bleeding-related complications nerve disorders....
Introduction: In an early-phase study, the combination of zanubrutinib plus obinutuzumab (ZO) was well tolerated and associated with early signal efficacy in patients (pts) follicular lymphoma (FL) (Tam et al. Blood Adv, 2020). ROSEWOOD (NCT03332017) is a phase 2, randomized study designed to assess safety ZO versus (O) relapsed/refractory (R/R) FL. Here, we present updated analysis median follow-up 20.2 months. Methods: Pts R/R FL (grade 1–3a) who received ≥2 lines therapy including...
The endothelium-dependent vascular injury, a primary pathological feature of angiotensin II (Ang II)-induced hypertension. This study aimed to explore the role and underlying mechanisms G protein-coupled receptor 39 (GPR39) in pathogenesis Ang II-induced For vivo studies, GPR39 knockout (KO) mice (C57BL/6 J, male) were generated administered for 4 weeks. expression was upregulated aorta hypertensive patients mice. ablation mitigated fibrosis, augmented vasodilation, inhibited endothelial...
Abemaciclib (oral CDK4 and 6 inhibitor) plus endocrine therapy (ET) as adjuvant treatment demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) distant relapse-free (DRFS) Chinese patients (pts) with Hormone Receptor (HR+)-positive human epidermal growth factor 2 (HER2)-negative high risk early breast cancer (EBC). This combination provided sustained clinical benefits at the pre-planned overall interim analysis (OS IA2). Here we present results of subset...
Introduction: Central nervous system (CNS) relapse is a rare, and usually fatal, event in diffuse large B-cell lymphoma (DLBCL). Improved identification of patients (pts) with high CNS risk needed. The International Prognostic Index (CNS IPI, Schmitz JCO 2016), clinical prognostic model that identifies pts higher risk, may be improved by integration biomarkers. Methods: was analysed DLBCL treated first-line obinutuzumab (G) or rituximab (R) plus CHOP the Phase III GOYA study (Vitolo Blood...